key: cord-0757855-tp9kk725 authors: Upert, Gregory; Luther, Anatol; Obrecht, Daniel; Ermert, Philipp title: Emerging peptide antibiotics with therapeutic potential date: 2020-12-30 journal: Med Drug Discov DOI: 10.1016/j.medidd.2020.100078 sha: f5ff9ec79120c32f43a8d7b61ef99248c1272190 doc_id: 757855 cord_uid: tp9kk725 This review covers some of the recent progress in the field of peptide antibiotics with a focus on compounds with novel or established mode of action and with demonstrated efficacy in animal infection models. Novel drug discovery approaches, linear and macrocyclic peptide antibiotics, lipopeptides like the polymyxins as well as peptides addressing targets located in the plasma membrane or in the outer membrane of bacterial cells are discussed. lower cytotoxicity against mammalian cells (HepG2; IC 50~2 50 µM) and low hemolysis (0.36% at 100 µM). In vivo, NOSO-95179 showed a 2 and 3 log CFU reduction of bacterial burden at 40 and 80 mg/kg, respectively, in a K pneumoniae ATCC 13883 lung efficacy model after subcutaneous injection in mice [27] . Currently, a new derivative NOSO-502 (3, Fig.1 ) coming from the lead optimization phase is in pre-clinical phase and developed by Nosopharm. Proline-rich antimicrobial peptides (PrAMPs) were first isolated from mammalian and insect cells for which they serve as host defence peptides against Gram-negative bacteria [28] [29] [30] . Their characteristics are a high content of proline and cationic amino acid residues (e.g. arginine) in repeated motifs (see Table 1 ). Despite a content of positive charges, PrAMPs do J o u r n a l P r e -p r o o f not exhibit an unspecific membranolytic mechanism of action typically observed for other cationic AMPs which show antimicrobial activity against both Gram-positive and Gramnegative bacteria [30] . In contrast, PrAMPS show good activity against Gram-negative bacteria without membrane disruption. The full D-enantiomer of PrAMP Bac7 does not display the same activity as the initial L-version pointing to a specific nonmembranolytic mechanism of action of Bac7 which contrasts to lytic AMPs where the D-enantiomers show the same activity [31] . It was shown that PrAMPs can translocate actively the membrane through permease/transporter uptake and have an intracellular mode of action [28, 29] . One of the first identified intracellular targets of PrAMPs was the bacterial heat shock protein DnaK. DnaK inhibition leads to protein misfolding and aggregation and ultimatly to bacterial death. X-ray structure determination and modelling studies of PrAMPs with E. Coli DnaK identified two binding sites [32] [33] [34] [35] . Subsequently, the 70S ribosome was identified as a new target for PrAMPs (i.e Api88, Api137, Onc72 and Onc112 [36, 37] ). Binding to the 70S ribosomal subunit by PrAMPs leads to inhibition of bacterial protein translation. The crystal structure of Onc112 (see Table 1 ) in complex with Thermus thermophilus 70S ribosome subunit has been solved [37] . Onc112 binds to the initiation complex preventing entry into the elongation phase and therefore the protein translation. The same binding mode with other PrAMPs was shown using X-Ray crystallography with Bac7 1-35 , Pyrrhocoricin, Metalnikowin and shorter oncocins derivatives OncΔ15-19 and OncΔVD (see Table 1 ) [38] . Roy et al. [39] showed that Onc112 binds to the 70S ribosome subunit around 50-fold stronger than to DnaK, highlighting the 70S ribosome as the main target of PrAMPs [39, 40] . Derivatives of Apidaecins (Api88 and Api137) and Oncocins (Onc 72 and Onc112) were tested in vivo using different routes of administration e.g. i.p., s.c. or i.v. Pharmacokinetic studies showed a low residence time for the different compounds with high clearance through the kidney [41] [42] [43] . The compounds have low stabilities in plasma which explains their low bioavailability. Interestingly, Onc72 showed an unexpected better in vivo activity than meropenem, despite its 44-fold lower in vitro activity [44] . This discrepancy between in vitro and in vivo activity was attributed to a negative effect on the in vitro activity by the MH-II media used according to the CLSI standard antimicrobial activity tests. At present, the high doses used for achieving in vivo efficacy in different models and the lack of safety data requires significant additional work for this interesting family of antibiotics to progress for further development. J o u r n a l P r e -p r o o f Apidaecin-Ib G-N-N-R-P-V-Y-I-P-Q-P-R-P-P-H-P-R-L 18 [28] Api137 TMG-Orn-N-N-R-P-V-Y-I-P-R-P-R-P-P-H-P-R-L-OH 18 [41, 45] Api88 TMG-Orn-N-N-R-P-V-Y-I-P-R-P-R-P-P-H-P-R-L-NH 2 18 [41, 45] Bac7(1-35) R-R-I-R-P-R-P-P-R-L-P-R-P-R-P-R-P-L-P-F-P-R-P-G-P-R-P-I-P-R-P-L-P-F-P 35 [46] Metalnikowin-I V-D-K-P-D-Y-R-P-R-P-R-P-P-N-M 15 [47] Pyrrhocoricin V-D-K-G-S-Y-L-P-R-P-T-P-P-R-P-I-Y-N-R-N 20 [48, 49] Onc112 V-D-K-P-P-Y-L-P-R-P-R-P-P-R-r-I-Y-N-r-NH2 19 [50] Onc72 V-D-K-P-P-Y-L-P-R-P-R-P-P-R-Orn-I-Y-N-Orn-NH 2 19 [50, 51] OncΔ15-19 V-D-K-P-P-Y-L-P-R-P-R-P-P-R 14 [38] OncΔVD K-P-P-Y-L-P-R-P-R-P-P-R-R-I-Y-N-R 17 [38] r = D-arginine; Orn = ornithine; TMG = N,N,N',N'-tetramethylguanidino; NH 2 = C-terminal primary amide 4. Lipopeptides Within the vast structural diversity of antimicrobial peptides, lipopeptides are of special importance highlighted by daptomycin and the polymyxins which are valuable commercial antibiotics of therapeutic use. Lipopeptides are characterized by the existence of a mostly macrocyclic peptidic core to which a hydrocarbon lipid tail (usually > C6) is linked via the N-terminus and may include hydroxy groups and unsaturation(s)). The lipid tail interacts with lipids of bacterial and potentially mammalian cell membranes generally enhancing the bactericidal effect of lipopeptide antibiotics. The macrocyclic peptidic core is important for specific interactions of the lipopeptide with lipid and/or protein targets. Nevertheless, the lipophilic hydrocarbon tail does not generally improve desirable drug properties like good aqueous solubility and is prone to generate unspecific binding to phospholipid bilayers, thus increasing potential offtarget effects. In the last decades, a large number of antimicrobial lipopeptides of natural source has been discovered. Besides the mentioned daptomycin and polymyxins, there are many additional interesting lipopeptides e.g. the actinocarbasin (arylomycin D; 19, Fig. 4) , globomycin, enopeptins, or friulimicin [11, 52] . Within this part of the review, we would like to focus only on a few selected examples of lipopeptide antibiotics that stand out based on their novel MoA, have available in vivo efficacy data and/or moved into preclinical or clinical development. Tridecaptins (Fig. 2 ) are non-ribosomally synthesized natural products within the class of linear cationic tridecapeptides which have been first isolated in 1978. Tridecapeptins display good antimicrobial activity against Gram-negative bacteria with single digit MICs [µg/mL] on Enterobacteriaceae and weaker activity against A. baumannii and moderate activity against P. aeruginosa [53, 54] . The antimicrobial activity against Gram-positive bacteria is generally moderate. SAR and MoA studies of one member of this family, Tridecaptin A 1 (TriA 1 ; 5, Fig. 2 ) isolated from Paenibacillus terrae have been described in more detail [54] [55] [56] . Cochrane et al. have observed that the structure of the lipid tail of TriA 1 could be varied without loss of antimicrobial activity [55] . The analogue OctTriA 1 (6) containing an octanoyl lipid chain fully retained its activity against all organisms [55] . In a first step, TriA 1 , but also the derivatives Ent-TriA 1 (enantiomer), Oct-TriA 1 and H-TriA 1 (unacylated TriA 1 ) bind with a similar affinity to lipopolysaccharide located in the outer membrane of Gram-negative bacteria [54] . However, the unacylated H-TriA 1 (4) as well as analogues with shorter lipid tail ( 64 µg/mL) [97] . The penetration hypothesis however would not explain the lack of activity against Gram-positive bacteria as pointed out by Smith et al. [98] , who studied the resistance development of the sensitive organism S. epidermidis to arylomycin A-C 16 Table 2 ). The sensitivity of the latter two organisms demonstrates that arylomycin penetrates the outer membrane. Biological consequences of SPase I inhibition and mechanisms of resistance have been recently reviewed and discussed by Craney and Romesberg [99] . The Pro residue which confers resistance interacts with the lipopeptide tail of arylomycin A 2 . Initial efforts to optimize the arylomycins focused on derivatives with altered lipopeptide tails [100] . Of particular interest was compound 24 ( Fig. 8 ) with improved activity against WT S. aureus NCTC 8325 compared to arylomycin A-C 16 (16) . No gain of activity was however Compound 27 however, with a glycyl aldehyde function -thought to form a covalent bond with the catalytic Ser-OH in the position of the scissile bond of the peptide substrate -was found to be more potent than arylomycin A-C 16 against the E.coli and S. aureus enzyme, demonstrating that the presence of the C-terminal carboxylate is not required for binding. The position of the electrophilic group is important as the homologues aldehyde 28 was reported to be inactive [97] . The increase in biochemical activity translated in an increased activity against MRSA (USA300) but didlike arylomycin A-C 16not exhibit activity against S. aureus 8325 or E.coli MG1655 [97] . Attempts to improve target accessibility in whole cells led to the synthesis of the arylomycin A-C 16 analogue 29 ( Fig. 8 ), which retained biochemical activity against E.coli and S. aureus SPase I [97] . Compound 29 retained activity against sensitive bacterial strains and gained weak activity against MRSA, which was explained by Liu et al. [97] by an interaction of the positively charged amine with the negatively charged teichoic acids of the Gram-positive cell wall. In compound 30, modification of the N-terminal peptide and introduction of positively charged groups were combined providing activity against Gram-negative pathogens (K. pneumoniae MIC = 0.5 µg/mL; P. aeruginosa MIC = 8 µg/mL) [91] . The molecule G0775 (31; Fig. 8 ), disclosed by Genentech scientists, integrates C-terminal electrophilic group, positively charged substituents and an altered lipopeptide tail [102] . A co-crystal structure of G0775 with Gram-negative SPase I revealed that the inhibitor binds like arylomycins and that the amino acetonitrile warhead forms a covalent bond not with Arylomycins were suggested by Romesberg and colleagues [99, 104] to be "latent antibiotics", which were in the past potent and had a broad-spectrum activity. Selection of resistance (and not poor intrinsic properties) then narrowed their spectrum by a single point mutation in SPase I. Producer strains in turn start to synthesize variants of arylomycins (such as actiocarbasin / arylomycin D) to regain activity. This "coevolution hypothesis for producer J o u r n a l P r e -p r o o f and susceptible organisms" [104] describes a situation comparable to that of clinically used antibiotics with by resistance compromised spectrum, leading to the development of next generation compounds [100] . Optimization of arylomycins resulted in the novel compound G0775 with potent broadspectrum activity against Gram-negative organisms, acting on a new antibiotic target. Serial passage experiments demonstrated that spontaneous resistance evolves with moderate frequency in the presence of low concentration (4 x MIC) of G0775, whereas with higher concentrations (8 -16 x MIC) the frequency was found to be very low [102] . The discovery of teixobactin (33; Fig. 9 ), published in 2015 [105] got a lot of attention both in academia [106, 107] and in the press [108] as it represented a new class of antibiotics with a novel MoA isolated by a new technique. New antibiotics are found only on rare occasions and teixobactin was discussed "to challenge the dogma of inevitable resistance" [109] as it was not possible to generate resistance in the laboratory [105] . Discovery of teixobactin and development of analogues was recently reviewed by Iyer et al. [110] and by McCarthy [111] . Karas et al. [112] summarized synthesis routes providing the natural product and analogues, structure-activity-relationship (SAR) as well as structural studies. Teixobactin (33) is produced by the soil-dwelling Gram-negative bacterium Eleftheria terrae by non-ribosomal peptide synthesis. Using a novel cultivation technique by isolation chip (iChip), the natural product antibiotic was produced by a bacterium that could previously not be cultivated by traditional methods. The iChip is a diffusion chamber allowing to isolate and grow bacteria in soil in the presence of natural nutrients and growth factors. Teixobactin was identified by screening of extracts from 10'000 (!) bacterial strains [105, 113, 114] . Teixobactin (33) al. [115] reported that MIC values of teixobactin analogues against S. aureus ATCC 29213 and B. subtilis ATCC 6051 were not significantly affected by the presence of 50% human serum. Pamar et al. [116] also observed no serum shift of the MIC values of two analogues tested against MRSA ATCC 33591 (Table 3) ). Teixobactin has bactericidal activity against S. aureus but was found to be inactive against Gram-negative bacteria like P. aeruginosa, K. pneumoniae or E. coli (MIC: 25 µg/mL). However, the strain E. coli asmB1 with defective outer membrane permeability barrier is sensitive to teixobactin (MIC: 2.5 µg/mL), indicating that the outer membrane protects the (Gram-negative) producer bacterium against it. Teixobactin was not cytotoxic against mammalian NIH/3T3 and HepG2 cells at 100 µg/mL, not hemolytic and did not exhibit genotoxicity. The compound showed minimal inhibition of the hERG channel and CYP isoenzymes, a half-life of 190 min in human plasma and good microsomal stability [105] . The aqueous solubility, however, was found to be poor as a 1:20 dilution of a 10 mg/mL DMSO stock solution with PBS buffer at pH 7.4 led to gelation [118] . A positive correlation of good antibiotic activity and propensity to form gels was reported by Nowick and colleagues [118, 119] for teixobactin analogues. Mode of action studies [105, 113] revealed, that teixobactin simultaneously inhibits the peptidoglycan and wall teichoic acid (WTA) biosynthesis triggering synergistic effects. It binds to the surface exposed peptidoglycan precursor lipid II (teixobactin / lipid II 2:1 stoichiometric complex) and to the WTA precursor lipid III. Binding to both targets relies on the interaction of teixobactin with the pyrophosphate and the first sugar moieties (Fig. 9 ). Teixobactin was also found to bind to undecaprenyl pyrophosphate. The apparent absence of resistance J o u r n a l P r e -p r o o f Journal Pre-proof development is in line with the targets being lipid molecules and not proteins. Lipid II is targeted by several other antibiotics, including the glycopeptide antibiotic vancomycin [120] . Vancomycin resistance occurred after 30 years of use in hospitals [4, 114] probably resulting from of horizontal gene transfer [114, 121] . Vancomycin interacts with the pentapeptide moiety of lipid II (specific interaction with the D-Ala-D-Ala motif) and is inactivated by binding to mature peptidoglycan. However, teixobactin does not bind to mature peptidoglycan (which does not have a pyrophosphate moiety). It is therefore active against vancomycin-intermediate S. aureus (VISA) strains [113] with modified cell walls including thicker peptidoglycan layers, and lower degree of cross linking, exposing more D-Ala-D-Ala binding sites to trap vancomycin [122] . Teixobactin was furthermore found to be active against vancomycin-resistant enterococci The research groups around Payne [123] , Li [124] , Nowick [118, 125] , Su [126] , Albericio [127] , Singh [128] and Brimble [129] developed syntheses of native teixobactin and/or analogues. Zhang and colleagues described a thioesterase-based chemo-enzymatic approach for the synthesis of teixobactin analogues [130] . A gram-scale synthesis of teixobactin, applying a convergent strategy, was recently reported by Rao and colleagues [131] . Many teixobactin analogues have been evaluated to establish a structure-activity-relationship (SAR). These studies as well as the synthetic access to the parent natural product and analogues have been summarized in detail by Karas et al. [112] . Therefore, only selected findings of the SAR studies are listed below. Residues of the tail region and of the macrocycle were found to contribute to antibacterial potency of teixobactin, which is abrogated by substitution of nonpolar amino acids with lysin of appropriate configuration [127] . The lysine scan was performed with Arg 10 -teixobactin (34) as a reference, where the hardly accessible L-allo-enduricididine residue in position 10 J o u r n a l P r e -p r o o f was replaced by arginine (Fig. 10) . The L-allo-End residue in position 10 can be replaced by positively charged amino acids maintaining similar activity than the natural product. Lys 10teixobactin (35) exhibited comparable potency against Gram-positve bacteria than Arg 10teixobactin (34) [125, 126] . Compound 35 was found to be non-hemolytic and not cytotoxic (RBCs and PBMCs showed a viability >90% at 64 µg/mL) [115] . A systematic alanine scan on Lys 10 -teixobactin (35) revealed that replacement of Lys 10 by alanine surprisingly results in the still moderately active compound Ala 10 -teixobactin (36) , which illustrates, that a positive charge in this position is not essential [118] . In line with this, also the L-citruline 10 analogue 37 described by Schumacher et al. [129] showed considerably reduced but not completely abrogated activity. Remarkably hydrophobic substitution leading to Leu 10 -and Ile 10 -teixobactin was tolerated; the corresponding analogues 38 and 39 were reported by Singh and colleagues to be in vitro against MRSA as potent as teixobactin (Table 3 ) [116, 132] . [116, 132] Ile (10) [133] . The disulfide macrocycle 43 (ring size increase by one atom) however was inactive [135] . While the diastereomers 44 and 45 lost activity, the enantiomer conserved the activity of 34 against four Gram-positive organisms tested [125] . The X-ray crystal structure of the truncated analogue 46 revealed, that the amide groups of the depsipeptide ring residues Arg 10 and Ile 11 and those of Ser 7 and D-Thr 8 and the guanidinium group of Arg 10 form a chloride anion binding site [134] . J o u r n a l P r e -p r o o f as the amide groups of Ser 7 and D-Thr 8 and the guanidinium group of Arg 10 create a cavity into which the chloride anion is accommodated [134] . Further more, the Nowick group described the X-ray structure of the Lys 10 -teixobactin homologue 47 (MIC against S. aureus 16 µg/mL; Fig. 12 ) with an α-N-methyl substituent at D-Gln 4 , which crystallized in the presence of sulfate ions as a hydrogen-bonded dimer [119] . The NH-groups of the depsipeptide macrocycle (D-Thr 8 , Ala 9 , Lys 10 Efforts made to prepare teixobactin analogues with improved activity against Gram-negative bacteria, for example by increasing the number of positively charged side chains (Fig. 13) , unfortunately gave so far minimal results only [115, 136] . Synergy between teixobactin analogues and outer membrane disrupting peptides has been reported by Ng et al. [122] and Chiorean et al. [117] . J o u r n a l P r e -p r o o f Ramoplanin A1 -A3 are macrocyclic glycolipodepsipeptides produced by Actinoplanes through non-ribosomal peptide synthesis (for details cf. Hoertz et al. [137] ). Ramoplanins difficile [138, 140] . Ramoplanin inhibits the cell wall synthesis, leading to bacterial death. The intracellular enzyme MurG, catalyzing the conversion of lipid I into lipid II has been proposed as target based on biochemical experiments using permeabilized bacterial cells and J o u r n a l P r e -p r o o f ramoplanin was thought to bind to the substrate [138, 141] . In the presence of an intact membrane, ramoplanin was proposed to block the polymerization of lipid II catalyzed by the bifunctional (transglycosylase, transpeptidase) penicillin-binding proteins PBP [138] by binding to the substrate, which is, as well as the enzyme, found on the external surface of the bacterial cellular membrane and thus accessible [138, 142] . Upon titration with the lipid II analogue 52 (Fig. 14) , ramoplanin complexes were found to polymerize to form fibrils, as evidenced by NMR-and CD spectra and electron microscopy [142] . Ramoplanin was reported to exhibit good aqueous solubility (>100 mg/mL) [143] . A solution structure of ramoplanin A2 monomer has been determined by NMR methods in water/DMSO-d 6 4:1 [144] but did not allow to understand how the molecule binds lipid II. Lo et al. [145] observed in D 2 O spectrum of ramoplanin A2 sharp resonances of a single species. In CD 3 OD, two distinct species were observed, with concentration-dependent relative signal intensities. Lo et al. [145] found the data to be consistent with the presence of a monomer and a C 2 -symmetric dimer (as both species had only one set of signals for each ramoplanin proton). The interface of the dimer comprises amino acid residues 10 -14 of each monomer and is stabilized by four hydrogen bonds. Based on their observations, Lo et al. [145] proposed ramoplanin A2 to exist as monomer in aqueous environment and to self-associate in proximity of the cellular membrane, creating lipid II binding sites. Enzyme-kinetic studies with E. coli PBP1b revealed a rapid rate increase with substrate (heptaprenyl lipid II) concentrations being more than half of the ramoplanin concentration which is in line with the antibiotic binding in 2:1 ratio to lipid II [146] . Boger and colleagues [150] performed an alanine scan for Dap 2 analogue of ramoplanin A2 aglycon (53; Fig. 15 ). The lactam 53 rather than the lactone was chosen for stability reasons (rapid hydrolysis of the lactone [151] ) and its easiest synthesis. The antibacterial activity of 53 against S. aureus ATCC 25923 is comparable to that of ramoplanin A2 aglycon [150, 151] . In particular, D-Orn 10 then also D-Hpg 3 , D-Hpg 7 and D-Orn 4 were shown to be most critical for activity against the S. aureus strain (Table 4 ). Based on their crystal structure, Hamburger et al. [147] explained these results: D-Orn 10 is positioned at the interface between hydrophilic and hydrophobic region of the ramoplanin A2 dimer and is thought to interact with the pyrophosphate moiety of lipid II. Walker et al. [138] compiled a list of lipid I analogues or fragments which bind to ramoplanin and reported the presence of the pyrophosphate to be essential. D-Hpg 3 was found to play a role in structure stabilization, D-Hpg 7 and D-Orn 4 in ligand recognition [147] . The following (simplified) model for lipid II recognition by ramoplanin II was proposed by Hamburger et al. [147] : Ramoplanin anchors (mediated by the N-acyl substituent) in the cellular membrane. The membrane stabilizes the dimer. The pyrophosphate group of lipid II forms a salt bridge with D-Orn 10 , lipid II polar head groups interact with the solvent exposed hydrophilic face of the dimer. The disaccharide (not important for activity [152] ) serves a solubility mediator. The The hydrolysis products 55 and 56 (Fig. 15 ) of ramoplanin A2 and ramoplanin A2 aglycon, respectively, were found to be markedly less potent (>250 -500-fold against S. aureus ATCC 25923) than the macrocyclic natural product [152] . Comparison of [Dap 2 ]ramoplanin aglycon (53) with [Dab 2 ]ramoplanin aglycon (54) also showed that the macrocycle is critical for antibacterial activity and introduction of the additional methylene group caused a > 100 fold loss in activity against S. aureus [151] . The N-terminal lipid substituent contributes to potency, which was 16-fold reduced upon replacement by an acetyl group (→ 57) [151] . The primary amide group of HAsn 2 , which is not present in 53, seems not to be required for activity. Compound 54 showed in vitro inhibition of the E. coli PBP1b-catalyzed transglycosylation reaction comparable to 53 or ramoplanin A2 (50) . The reduced potency observed in the antimicrobial assay resulted from an increased tendency of the compound to self-aggregate [153] rather than from reduced capability to inhibit the enzymatic reaction. Similarly, replacement of the lipid substituent of ramoplanin A2 aglycon by an acetyl group resulted in MIC value increase (reduced antimicrobial potency) without influencing the in vitro inhibition of the transglycosylase. This is in line with the key role of the lipid substituent in targeting the bacterial membrane [153] . Ramoplanin was demonstrated by Cheng et al. [143] applying SPR methods to bind in concentration dependent manner to anionic ("bacterial") membranes preferentially over zwitterionic ("mammalian") ones. Ramoplanin is not orally absorbed and in the plasma the lactone was described to be rapidly hydrolyzed [150, 151, 154] . Jabes et al. [148] , however, reported a half-life of 3.8 h in rat plasma. The local tolerability is low if injected i.v. (swelling and progressive necrotiazation at injection site, hemolysis revealed by urine discoloration within 24 h if dosed to rats at 10 mg/kg) [149, 154] . These properties are limiting the therapeutic application. Orally administered ramoplanin A2 was in clinical trials [10, 155, 156] and was approved by the FDA as antibiotic against gut colonization by vancomycin-resistant enterococcus (VRE) and against C. difficile [13] . In 2017 and in 2019, no clinical trials were ongoing with ramoplanin [157, 158] or there was no recent information. Disease recurrence is observed in ca 25% of the patients after standard treatment against C. difficile and is thought to be at least in part a consequence of spores that remain in the gut J o u r n a l P r e -p r o o f lumen, tolerating the treatment of the acute infection. In an in vitro model, ramoplanin showed activity against C. difficile spores. Spore counts were reported by Kraus et al. [159] to be below the level of detection for 28 days after 30 minutes exposure to ramoplanin at 300 µg/mL (concentration found in feces). Vancomycin (500 µg/mL)-or metronidazole (10 µg/mL)-exposure however did not suppress spore counts. Kraus et al. postulated that ramoplanin adheres to the exosporium (an outer surface layer protecting the spores and preventing the release of inflammation triggering signals) ready to attack germinating cells. Ramoplanin might thus help to reduce relapse rates. Nanotherapeutics seemingly planned in 2016 a clinical investigation of the antispore properties of ramoplanin [155] . Attempts to overcome the limitation of ramoplanin to gastrointestinal and topical applications and to gain access to systemic use included the development of protecting formulations and the synthesis of analogues and derivatives with better stability/tolerability properties. Ramoplanin administered in emulsions containing intralipid [160] as well as cyclodextrinbased formulations [154] have been reported to improve tolerability (in animals) while maintaining antimicrobial effectiveness (in vivo or in vitro). Modification of the lipid substituent led to compound 51 ( Fig. 14 Figure 16 ) was first described in 1996 [161] . Thanatin showed antibacterial activity against some Gram-positive and Gram-negative bacteria, and also J o u r n a l P r e -p r o o f antifungal activity. The all-D thanatin enantiomer was significantly less active, in particular against E.coli. The MoA was not known until recently [16, 162, 163] . A close analogue of thanatin, S-Thanatin (Thr 15 replaced by Ser), binds to lipopolysaccharide (LPS) and showed good in vivo efficacy in a mouse model of septic shock [164] (ED 50 = 7 mg/kg). Alanine-scanning studies showed that residues in the disulfide loop seem critical for antimicrobial activity [165] . S-Thanatin was well tolerated in mice [166] . As shown by NMR, thanatin forms in solution a β-hairpin-like structure from residue 8 to the C-terminus stabilized by the disulfide loop and three C-terminal residues [167] . The hairpin structure has been confirmed by an NMR solution structure in zwitterionic micelles [168] . The hairpin conformation seems to be relevant for activity, especially against Gram-negative bacteria [165] . In summary, MoA studies show that thanatin has some membrane permeabilization characteristics which explains its relatively weak antimicrobial activity against Gram-positive bacteria and fungi. However, additional studies show that the promising Gram-negative activity of thanatin is mainly driven by its binding to LptA by inhibition of LPS export. The thanatin example is a very interesting show case highlighting that AMPs can exert different MoAs. On one hand thanatin targets rather unspecifically bacterial and fungal membranes whereas in Gram-negative bacteria it addresses a specific protein target. Naturally occurring antimicrobial peptides make interesting starting points for the design and synthesis of biologically active peptide mimetics. Phenotypic screening of a library of protein J o u r n a l P r e -p r o o f epitope mimetics (PEMs) [170, 171] , inspired by antimicrobial peptides such as protegrin I, on a panel of Gram-negative bacteria gave initial hits with interesting antimicrobial activity against Pseudomonas aeruginosa, an important pathogen causing ventilator-and hospital associated/acquired bacterial pneumonia (VABP and HABP). A significant lead optimization effort led to highly potent and selective antibiotics such as POL7001 and POL7080 (59; Fig. 17 ) with excellent efficacy in various mouse infection models [15] . POL7080 (Murepavadin) was selected as a clinical candidate for further development [172] . By linking two macrocyclic pharmacophores against two essential bacterial targets, LPS and BamA, located in proximity at the outer-membrane of Gram-negative bacteria, a novel class of antibiotics with potent activity against carbapenem-resistant Pseudomonas aeruginosa and Enterobacteriacea (WHO priority-1 pathogens) was discovered. First hits (e.g. 60; Fig. 18) with good activity against MDR-XDR strains were discovered by phenotypic screening of a library constituted of 14-amino acid macrocyclic β-hairpin mimetics [7] derived from active peptide sequences of antimicrobial peptides, such as protegrin-1 or murepavadin [15] . While After further optimization of ADMET properties such as cytotoxicity on different cell lines, a new scaffold was found where the hairpin structure was stabilized by a disulfide bond as represented by chimera 62 (Fig. 20) , which showed an excellent in vitro and in vivo profile. protein and an essential part of the BAM (β-barrel assembly machinery) complex, which is critical for proper folding and insertion of outer membrane protein precursors into the outer membrane [180] . Optimized lead compounds are currently under preclinical evaluation. Whereas most of the large successful antibiotic classes were discovered from soil microorganisms (mainly Actinomycetes), darobactin was isolated from Photorhabdus symbionts of nematodes [18, 177, 178] . Darobactin (63; Fig. 21 ) is a ribosomally synthesized peptide and features an unusual structure with two fused macrocyclic rings containing two substituted tryptophan indole rings forming a compact hairpin-like structure. J o u r n a l P r e -p r o o f BamA was also confirmed by NMR studies [18] . BamA is an essential protein and a member of the BAM complex critically involved in folding and insertion of β-barrel outer membrane proteins [180] . Arenicin-1 and -2 are small antimicrobial peptides isolated from coelomocytes of marine lugworm Arenicola marina ( Fig. 22 ; Table 5 ; [181] ) consisting of one disulfide bond and are J o u r n a l P r e -p r o o f rich in arginine and hydrophobic amino acids. Arenicin-3, originally isolated from the same lugworm, contains nine hydrophobic residues, four positively charged arginine residues and two disulfide bonds (Cys 3 -Cys 20 and Cys 7 -Cys 16 ) which stabilize an amphipathic β-hairpin structure. NMR solution structures (deposited as PDB5v0y and BMRB30259) revealed that the two β-strands are connected by a type I'β-turn, formed by Asn 11 and Gly 12 , and the βsheet is further stabilized by four hydrogen bonds [182] . Arenicin-3 shows good activity against a variety of Gram-negative bacteria [182, 183] , however, shows high protein binding (99%) to serum components [183] , and was discussed to be hemolytic and cytotoxic [182] . *) NZ17074 is abbreviated as N1 in [184] and as N4 in [186] . NZ17074 is an arenicin-3 variant, which was identified by Neve et al. from Novozyme by high throughput screening of yeast libraries [183, 187] . NZ17074 differs from arenicin-3 in positions 5 (Y→N) and 17 (Y→H). Based on the analysis of CD spectra, Wang et al. [186] reported NZ17074 to adopt in aqueous solution a secondary structure with β-sheet character, however, in lipophilic environment, in the presence of 10 mM sodium dodecyl sulfate, an αhelical structure was induced. Synthetic NZ17074 was obtained by solid phase peptide synthesis applying Fmoc chemistry [185] . Recombinant NZ17074 (rNZ17074) was produced in yeast (Pichia pastoris) by expression as SUMO3-NZ17074 fusion protein, followed by purification, cleavage to release rNZ17074, and final purification. Recombinant NZ17074 has an additional Pro at the Nterminus; it was demonstrated to be active in antibacterial assays like NZ17074 [188] . It is worth noting, that recombinant 15 N-labelled AA-139 (a further arenicin-3 analogue, see below) was expressed as His-tagged SUMO fusion protein in a bacterial system (E. coli) described by Zhang et al. [189] . [183, 186] . Weaker activity (MICs of 2 -32 µg/mL) has been reported against a selection of Gram-positive bacteria [186] . In addition, NZ17074 exhibits antifungal activity against Candida albicans (MIC 4 -16 µg/mL) [185, 186] and low to moderate cytotoxicity against porcine intestinal epithelial cells and mouse peritoneal macrophages [186] . As compared to arenicin-3, NZ17074 shows reduced serum protein binding (79%, [183,187]) and was found to bind LPS as determined by MIC and probe displacement methods. The antibacterial mechanism against E. coli cells proposed and investigated by Wang et al. Yang et al. [184] reported the evaluation of seven analogues of NZ17074 which were prepared with the objective to reduce cytotoxicity. Essential for antimicrobial activity were the Val residues in position 6, 8, 13 and 15 as well as Asn in positions 11 and 21 [184, 187] . Two analogues (Fig. 23 ) with potent antibacterial activity were obtained: in N2 the Gly residues in position 1 and 12 were replaced by Ala; in N6 the two Cys residues in position 3 and 20 were replaced by Ala, leading to a molecule with only one disulfide bond. µg/mL (N6)) [184] . Like parent NZ17074, N2 and N6 were found to potently bind to LPS (comparable to polymyxin B) as determined by a probe displacement assay. Docking calculations suggest that the three molecules differ in the sites of interaction with lipid A [184] . In vivo activity of N2 and N6 was evaluated in mice peritonitis models (inoculation with E. reported to be more efficacious than polymyxin B [184] . AA-139 (Fig. 24) is a synthetic analogue derived from arenicin-3, prepared by solid phase peptide synthesis. Val in position 8 and 13 of arenicin-3 were replaced by Ala; Tyr in position 9 by Arg reducing the lipophilicity and increasing the overall charge (Fig. 24 , Table 5 ). The peptide was obtained as a member of a library which was based on an alanine scan and removal or mutation of one to four residues at varying positions, while keeping the Cys residues to maintain integrity of the secondary structure [182] . AA-139 as well as the analogues NZ17143 and NZ17224 showed higher CC 50 values against three human cell lines (Table 7) [182] concluded that there was no binding to lipid A, as in the SPR experiment no significant difference in binding was observed. These authors also tested the permeabilization activity of arenicin-3 variants in several assays. The results were consistent with binding to and disruption of bacterial membranes, cell permeabilization, cytoplasmic leakage and cell death. Phospholipid transport was also associated with the mechanism of action of arenicin-3 in E. coli. Whole-genome sequencing of 20 days serial passage (forced resistance) isolates of E. coli ATCC 25922 in the presence of arenicin-3 led to a point mutation T32G in the mlaC gene, which translated into the L11R replacement in the protein. The mla operon (regulating the expression of the phospholipid transport system mlaABCDEF) maintains the outer membrane asymmetry [182] . Good efficacy for i.v. administered AA-139 was demonstrated in neutropenic murine peritonitis and thigh infection models [182] . Aerolized AA-139, generated by a Hudson RCI Micro-mist nebulizer, was tested in a pneumonia model (P. aeruginosa ATCC 27853). When infected mice were exposed 2, 12 and 24 h after infection to aerosol of AA-139 (30 mg/mL) for 30 min, a 6.6 log reduction of bacterial burden in the lung was reported. To determine the exactly delivered dose was not possible. The PK profile of inhaled AA-139 showed high J o u r n a l P r e -p r o o f concentrations in epithelial lining fluid (ELF) and low concentrations in plasma [182] . Finally, AA-139 was also demonstrated to be active in a urinary tract infection model; the analogue NZ17143 showed similar efficacy in this model [182] . Target organ toxicity was reported to affect the kidney with tubular nephropathy after i.v. dosing at 20, 25 or 30 mg/kg of AA-139 per day to minipigs for seven days. Severity increase was found to be dose related. A NOAEL of 20 mg/kg AA-139 per day (10 times the dose required for efficacy in murine infection models) by i.v. administration over 2 h once or twice daily was reported in mice. For inhaled AA-139, the NOAEL was 20 mg/kg per day in mice [182] . Natural products have been the cornerstone of antibiotic discovery and development. Among fold more potent lactam 42 [133] . The disulfide macrocycle 43 (ring size increase by one atom) however was inactive [135] . While the diastereomers 44 and 45 lost activity, the enantiomer conserved the activity of 34 against four Gram-positive organisms tested [125] . The X-ray crystal structure of the truncated analogue 46 revealed, that the amide groups of the depsipeptide ring residues Arg 10 and Ile 11 and those of Ser 7 and D-Thr 8 and the guanidinium group of Arg 10 form a chloride anion binding site [134] . [150, 151] . Structures of the hydrolysis products 55 and 56 of ramoplanin A2 and ramoplanin A2 aglycon [152] . Apidaecin-Ib G-N-N-R-P-V-Y-I-P-Q-P-R-P-P-H-P-R-L 18 [28] Api137 TMG-Orn-N-N-R-P-V-Y-I-P-R-P-R-P-P-H-P-R-L-OH 18 [41, 45] Api88 TMG-Orn-N-N-R-P-V-Y-I-P-R-P-R-P-P-H-P-R-L-NH 2 18 [41, 45] Bac7(1-35) R-R-I-R-P-R-P-P-R-L-P-R-P-R-P-R-P-L-P-F-P-R-P-G-P-R-P-I-P-R-P-L-P-F-P 35 [46] Metalnikowin-I V-D-K-P-D-Y-R-P-R-P-R-P-P-N-M 15 [47] Pyrrhocoricin V-D-K-G-S-Y-L-P-R-P-T-P-P-R-P-I-Y-N-R-N 20 [48, 49] Onc112 V-D-K-P-P-Y-L-P-R-P-R-P-P-R-r-I-Y-N-r-NH2 19 [50] Onc72 V-D-K-P-P-Y-L-P-R-P-R-P-P-R-Orn-I-Y-N-Orn-NH 2 19 [50, 51] OncΔ15-19 V-D-K-P-P-Y-L-P-R-P-R-P-P-R 14 [38] OncΔVD K-P-P-Y-L-P-R-P-R-P-P-R-R-I-Y-N-R 17 [38] r = D-arginine; Orn = ornithine; TMG = N,N,N',N'-tetramethylguanidino; NH 2 = C-terminal primary amide [116, 132] Ile(10)-teixobactin (39) 0.25 0.25 [116, 132] D-Arg(4)-Leu(10)-teixobactin (40) 0.125 - [132] D-Arg(4)-Leu(10)-teixobactin (40; structure not shown) was evaluated in vivo in a topical instillation in a mouse-eye model of S. aureus ATCC 29213 (MIC <0.0625 µg/mL) keratitis. As compared to untreated mice, the peptide 40 was found to reduce bacterial bioburden (by >99%) and to decrease corneal edema [132] . Reported molecular weight (MW) of peptides in different literature references may vary depending on considered oxidation state of Cys residues. *) NZ17074 is abbreviated as N1 in [184] and as N4 in [186] . No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis Antimicrobial resistance: tackling a crisis for the health and wealth of nations New antibiotics from Nature's chemical inventory The global preclinical antibacterial pipeline Antibiotics in the clinical pipeline in Advances in macrocyclic peptide-based antibiotics Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study The Vast Structural Diversity of Antimicrobial Peptides Antimicrobial peptides under clinical investigation Gram-negative bacilli-derived peptide antibiotics developed since Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies Multiple ways to kill bacteria via inhibiting novel cell wall or membrane targets Antimicrobial Agents That Inhibit the Outer Membrane Assembly Machines of Gram-Negative Bacteria Peptidomimetic Antibiotics Target Outer-Membrane Biogenesis in Pseudomonas aeruginosa Thanatin targets the intermembrane protein complex required for lipopolysaccharide transport in Escherichia coli Chimeric peptidomimetic antibiotics against Gram-negative bacteria A new antibiotic selectively kills Gram-negative pathogens Intracellular Targeting Mechanisms by Antimicrobial Peptides Antibacterial Agents that Cause Miscoding by Binding at a New Ribosomal Site The Science of Antibiotic Discovery Platforms for antibiotic discovery ESKAPEing the labyrinth of antibacterial discovery Systems-level antimicrobial drug and drug synergy discovery Bacteria of the Genus Xenorhabdus Novel peptide derivatives as antibiotics Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity Apidaecin-Type Peptide Antibiotics Function through a Nonporeforming Mechanism Involving Stereospecificity Proline-rich antimicrobial peptides targeting protein synthesis Proline-rich antimicrobial peptides: converging to a non-lytic mechanism of action Dual mode of action of Bac7, a proline-rich antibacterial peptide The Antibacterial Peptide Pyrrhocoricin Inhibits the ATPase Actions of DnaK and Prevents Chaperone-Assisted Protein Folding † The Antibacterial Effect of a Proline-Rich Antibacterial Peptide A3-APO Structural Studies on the Forward and Reverse Binding Modes of Peptides to the Chaperone DnaK Structural Identification of DnaK Binding Sites within Bovine and Sheep Bactenecin Bac7 Insect-Derived Proline-Rich Antimicrobial Peptides Kill Bacteria by Inhibiting Bacterial Protein Translation at the 70 S Ribosome The proline-rich antimicrobial peptide Onc112 inhibits translation by blocking and destabilizing the initiation complex Structures of proline-rich peptides bound to the ribosome reveal a common mechanism of protein synthesis inhibition The mechanism of inhibition of protein synthesis by the proline-rich peptide oncocin Mechanism of actions of Oncocin, a proline-rich antimicrobial peptide, in early elongation revealed by single-molecule FRET Continuous Subcutaneous Delivery of Proline-Rich Antimicrobial Peptide Api137 Provides Superior Efficacy to Intravenous Administration in a Pharmacokinetics and in vivo efficacy of optimized oncocin derivatives Oncocin Onc72 is efficacious against antibioticsusceptible Klebsiella pneumoniae ATCC 43816 in a murine thigh infection model: Efficacy of Onc72 in Susceptible K. pneumoniae ATCC 43816 in Thigh Infection Model Api88 Is a Novel Antibacterial Designer Peptide To Treat Systemic Infections with Multidrug-Resistant Gram-Negative Pathogens Purification, composition, and activity of two bactenecins, antibacterial peptides of bovine neutrophils The inducible antibacterial peptides of the Hemipteran insect Palomena prasina: Identification of a unique family of prolinerich peptides and of a novel insect defensin Novel inducible antibacterial peptides from a hemipteran insect, the sap-sucking bug Pyrrhocoris apterus Pyrrhocoricin, a proline-rich antimicrobial peptide derived from insect, inhibits the translation process in the cell-free Escherichia coli protein synthesis system VDKPPYLPRPRPPRRIYNR-NH 2 ): A Novel Antibacterial Peptide Optimized against Gram-Negative Human Pathogens Oncocin derivative Onc72 is highly active against Escherichia coli in a systemic septicaemia infection mouse model A Glutamate Mutase Is Involved in the Biosynthesis of the Lipopeptide Antibiotic Friulimicin in Actinoplanes friuliensis Isolation of tridecaptins A, B and C. Studies on antibiotics from the genus Bacillus. XXIII Antimicrobial lipopeptide tridecaptin A 1 selectively binds to Gram-negative lipid II Synthesis and Structure-Activity Relationship Studies of N-Terminal Analogues of the Antimicrobial Peptide Tridecaptin A 1 Biochemical, Structural, and Genetic Characterization of Tridecaptin A 1 , an Antagonist of Campylobacter jejuni Tridecaptin M, a New Variant Discovered in Mud Bacterium, Shows Activity against Colistin-and Extremely Drug-Resistant Enterobacteriaceae Rational design of new cyclic analogues of the antimicrobial lipopeptide tridecaptin A 1 Bifunctional antimicrobial conjugates and hybrid antimicrobials Synthesis of Tridecaptin-Antibiotic Conjugates with in Vivo Activity against Gram-Negative Bacteria Cultureindependent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens Discovering antibiotics from the global microbiome Total Synthesis of Malacidin A by β-Hydroxyaspartic Acid Ligation-Mediated Cyclization and Absolute Structure Establishment Lipopeptides from Bacillus and Paenibacillus spp.: A Gold Mine of Antibiotic Candidates Acute Renal Failure Due to Overdosage of Colistin Adverse Effects of Sodium Colistimethate: Manifestations and Specific Reaction Rates During 317 Courses of Therapy A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-Negative Pneumonia Nephrotoxicity of intravenous colistin: a prospective evaluation Pandrugresistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: Characteristics and outcome in a series of 28 patients Molecular mechanisms of polymyxin resistance: knowns and unknowns A colistin crisis in India Emergence of plasmidmediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study An Approach to Measuring Colistin Plasma Levels Regarding the Treatment of Multidrug-Resistant Bacterial Infection Polymyxin: Alternative Mechanisms of Action and Resistance Structure−Activity Relationships of Polymyxin Antibiotics Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections Polymyxins: a new hope in combating Gramnegative superbugs Design of Next Generation Polymyxins with Lower Toxicity: The Discovery of SPR206 Uptake of Polymyxin B into Renal Cells Synthesis of octapeptin C4 and biological profiling against NDM-1 and polymyxin-resistant bacteria Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative Bacteria Discovery of Novel Polymyxin-Like Antibiotics Novel derivatives of polymyxins Bacterial Signal Peptidases Crystallographic and Biophysical Analysis of a Bacterial Signal Peptidase in Complex with a Lipopeptide-based Inhibitor Arylomycins A and B, New Biaryl-bridged Lipopeptide Antibiotics Produced by Streptomyces sp. Tue 6075. II. Structure Elucidation Imaging Mass Spectrometry and Genome Mining via Short Sequence Tagging Identified the Anti-Infective Agent Arylomycin in Streptomyces roseosporus Biosynthesis of L-p-hydroxyphenylglycine, a nonproteinogenic amino acid constituent of peptide antibiotics Structural and Initial Biological Analysis of Synthetic Arylomycin A 2 Scalable Access to Arylomycins via C-H Functionalization Logic Mechanism of Action of the Arylomycin Antibiotics and Effects of Signal Peptidase I Inhibition Peptide binding to a bacterial signal peptidase visualized by peptide tethering and carrier-driven crystallization Crystal structure of a bacterial signal peptidase in complex with a β-lactam inhibitor Synthesis and Characterization of the Arylomycin Lipoglycopeptide Antibiotics and the Crystallographic Analysis of Their Complex with Signal Peptidase Novel Lipoglycopeptides as Inhibitors of Bacterial Signal Peptidase I Efforts toward broadening the spectrum of arylomycin antibiotic activity Broad-Spectrum Antibiotic Activity of the Arylomycin Natural Products Is Masked by Natural Target Mutations The inhibition of type I bacterial signal peptidase: Biological consequences and therapeutic potential Initial Efforts toward the Optimization of Arylomycins for Antibiotic Activity Broadening the Spectrum of β-Lactam Antibiotics through Inhibition of Signal Peptidase Type I Optimized arylomycins are a new class of Gram-negative antibiotics Peptide Antibiotic Complexes And Methods Of Use Thereof Initial Analysis of the Arylomycin D Antibiotics A new antibiotic kills pathogens without detectable resistance Teixobactin: A New Class of Antibiotic Multiple Attack on Bacteria by the New Antibiotic Teixobactin New Antibiotic Stirs Hope Against Resistant Bacteria New approaches to antimicrobial discovery Teixobactins: a new class of 21st century antibiotics to combat multidrug-resistant bacterial pathogens Teixobactin: a novel anti-infective agent Synthesis and structure−activity relationships of teixobactin Dual Targeting of Cell Wall Precursors by Teixobactin Leads to Cell Lysis An irresistible newcomer Teixobactin analogues reveal enduracididine to be non-essential for highly potent antibacterial activity and lipid II binding Dissecting the Binding Interactions of Teixobactin with the Bacterial Cell-Wall Precursor Lipid II Alanine scan reveals modifiable residues in teixobactin X-ray Crystallographic Structure of a Teixobactin Derivative Reveals Amyloid-like Assembly Lipid II as a target for antibiotics Glycopeptide Antibiotic Resistance Genes in Glycopeptide-Producing Organisms Rational Design and Synthesis of Modified Teixobactin Analogues: In Vitro Antibacterial Activity against Staphylococcus aureus , Propionibacterium acnes and Pseudomonas aeruginosa Total Synthesis of Teixobactin Synthesis and structure-activity relationship of teixobactin analogues via convergent Ser ligation Elucidation of the Teixobactin Pharmacophore Synthesis and structure-activity relationship studies of teixobactin analogues Lysine Scanning of Arg 10 -Teixobactin: Deciphering the Role of Hydrophobic and Hydrophilic Residues Efficient total syntheses and biological activities of two teixobactin analogues Synthesis and biological evaluation of novel teixobactin analogues Thioesterase-Mediated Synthesis of Teixobactin Analogues: Mechanism and Substrate Specificity Gram-scale total synthesis of teixobactin promoting binding mode study and discovery of more potent antibiotics Design and Syntheses of Highly Potent Teixobactin Analogues against Staphylococcus aureus , Methicillin-Resistant Staphylococcus aureus (MRSA), and Vancomycin-Resistant Enterococci (VRE) in Vitro and in Vivo Developing Equipotent Teixobactin Analogues against Drug-Resistant Bacteria and Discovering a Hydrophobic Interaction between Lipid II and Teixobactin X-ray crystallographic structure of a teixobactin analogue reveals key interactions of the teixobactin pharmacophore Cysteines and Disulfide-Bridged Macrocyclic Mimics of Teixobactin Analogues and Their Antibacterial Activity Evaluation against Methicillin-Resistant Staphylococcus Aureus (MRSA) Converting Teixobactin into a Cationic Antimicrobial Peptide (AMP) Studies on the biosynthesis of the lipodepsipeptide antibiotic Ramoplanin A2 Chemistry and Biology of Ramoplanin: A Lipoglycodepsipeptide with Potent Antibiotic Activity Functional and biochemical analysis of a key series of ramoplanin analogues Production of Ramoplanin and Ramoplanin Analogs by Actinomycetes Inhibition of peptidoglycan biosynthesis by ramoplanin A New Mechanism of Action Proposed for Ramoplanin Ramoplanin at Bactericidal Concentrations Induces Bacterial Membrane Depolarization in Staphylococcus aureus 3D Structure of Ramoplanin: A Potent Inhibitor of Bacterial Cell Wall Synthesis † , ‡ A New Structure for the Substrate-Binding Antibiotic Ramoplanin Ramoplanin Inhibits Bacterial Transglycosylases by Binding as a Dimer to Lipid II A crystal structure of a dimer of the antibiotic ramoplanin illustrates membrane positioning and a potential Lipid II docking interface Pharmacological Properties of NAI-603, a Well-Tolerated Semisynthetic Derivative of Ramoplanin Synthesis and Preliminary Biological Characterization of New Semisynthetic Derivatives of Ramoplanin Alanine Scan of [ L -Dap 2 ]Ramoplanin A2 Aglycon: Assessment of the Importance of Each Residue Total Synthesis and Examination of Three Key Analogues of Ramoplanin: A Lipoglycodepsipeptide with Potent Antibiotic Activity Total Synthesis of the Ramoplanin A2 and Ramoplanose Aglycon Dissecting Ramoplanin: Mechanistic Analysis of Synthetic Ramoplanin Analogues as a Guide to the Design of Improved Antibiotics Novel antibiotics in development to treat Clostridium difficile infection Novel Antimicrobials for the Treatment of Clostridium difficile Infection Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. Geneva: World Health Organization Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline. Geneva: World Health Organization Ambush of Clostridium difficile Spores by Ramoplanin: Activity in an In Vitro Model New injectable formulations containing ramoplanin. WO2000006119A1 Structure-activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides Thanatin Impairs Lipopolysaccharide Transport Complex Assembly by Targeting LptC-LptA Interaction and Decreasing LptA Stability The antimicrobial peptide thanatin disrupts the bacterial outer membrane and inactivates the NDM-1 metallo-β-lactamase Selective toxicity of antimicrobial peptide S-thanatin on bacteria Role of Amino Acid Residues within the Disulfide Loop of Thanatin, a Potent Antibiotic Peptide Subacute toxicity of antimicrobial peptide S-thanatin in ICR mice Solution structure of thanatin, a potent bactericidal and fungicidal insect peptide, determined from proton twodimensional nuclear magnetic resonance data NMR structure and localization of the host defense antimicrobial peptide thanatin in zwitterionic dodecylphosphocholine micelle: Implications in antimicrobial activity Structural basis of unidirectional export of lipopolysaccharide to the cell surface Protein epitope mimetic macrocycles as biopharmaceuticals β-Hairpin protein epitope mimetic technology in drug discovery Murepavadin: a new antibiotic class in the pipeline Inhibition of Lipopolysaccharide Transport to the Outer Membrane in Pseudomonas aeruginosa by Peptidomimetic Antibiotics A Peptidomimetic Antibiotic Interacts with the Periplasmic Domain of LptD from Pseudomonas aeruginosa Efficacy of the Novel Antibiotic POL7001 in Preclinical Models of Pseudomonas aeruginosa Pneumonia Recent Progress in the Discovery of Macrocyclic Compounds as Potential Anti-Infective Therapeutics New antibiotics target bacterial envelope The Fellowship of the Rings: Macrocyclic Antibiotic Peptides Reveal an Anti-Gram-Negative Target Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide Structure of a nascent membrane protein as it folds on the BAM complex Purification and primary structure of two isoforms of arenicin, a novel antimicrobial peptide from marine polychaeta Arenicola marina An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria NZ17074: An Arenicin-3 variant found by HTS screening of yeast libraries Antibacterial and detoxifying activity of NZ17074 analogues with multi-layers of selective antimicrobial actions against Escherichia coli and Salmonella enteritidis Candidacidal mechanism of the arenicin-3-derived peptide NZ17074 from Arenicola marina Combined Systems Approaches Reveal a Multistage Mode of Action of a Marine Antimicrobial Peptide against Pathogenic Escherichia coli and Its Protective Effect against Bacterial Peritonitis and Endotoxemia Antimicrobial peptide variants and polynucleotides encoding same Recombinant production of the antimicrobial peptide NZ17074 in Pichia pastoris using SUMO3 as a fusion partner Elucidating the Lipid Binding Properties of Membrane-Active Peptides Using Cyclised Nanodiscs